Avant Diagnostics, Inc., a commercial-stage molecular data-generating company, focuses on the development and commercialization of proprietary data-generating assays that provide information for physicians and patients in the areas of cancers.
The last earnings update was 60 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Avant Diagnostics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Avant Diagnostics's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Avant Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Avant Diagnostics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Avant Diagnostics's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Avant Diagnostics's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Avant Diagnostics is high growth as no earnings estimate data is available.
Unable to determine if Avant Diagnostics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Avant Diagnostics's filings and announcements here.
Avant Diagnostics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Avant Diagnostics's finances.
The net worth of a company is the difference between its assets and liabilities.
Avant Diagnostics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Avant Diagnostics has no long term commitments.
This treemap shows a more detailed breakdown of
Avant Diagnostics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 1.1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Michael I. Ruxin, also known as Mick, M.D., is the President and Chief Executive Officer of Avant Diagnostics, Inc. since May 25, 2018 and has been its Director since June 22, 2018. Dr. Ruxin was the Vice President of Global Software Strategies at Haemonetics Corp. since 2010. Dr. Ruxin was the Founder, Chief Executive Officer, and Chairman at Global Med Technologies, Inc. He serves as the Chairman and Chief Executive Officer of Wyndgate Technologies, Inc. He served as the Chief Accounting Officer and Chief Financial Officer of Global Med Technologies Inc. since February 25, 2004. Prior to Global Med, Dr. Ruxin founded and was the Chairman and Chief Executive Officer of National MRO, an international corporation. He was Chief of two Emergency Departments in Denver, Colorado. He is a licensed physician in California and Colorado. Dr. Ruxin received a B.A. degree from the University of Pittsburgh and M.D. degree from the University of Southern California.
Insufficient data for Mick to compare compensation growth.
Mick's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Avant Diagnostics management team is less than 2 years, this suggests a new team.
Interim Chief Financial Officer
Chief Scientific Officer
Chairman & CEO of Arrayit Corporation
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Avant Diagnostics board of directors is less than 3 years, this suggests a new board.
Avant Diagnostics, Inc., a commercial-stage molecular data-generating company, focuses on the development and commercialization of proprietary data-generating assays that provide information for physicians and patients in the areas of cancers. It owns license and distribution right for OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. The company was founded in 2009 and is based in Washington, District of Columbia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.